Revenir à l'agenda
Séquences d'hormonothérapie associées à la radiothérapie des cancers de prostate localisés et impact sur les LUTS
Choix de l'ADT chez le patient métastatique
Hormonothérapie et santé cardiovasculaire : Optimisation des pratiques pour les patients atteints de cancer de la prostate à haut risque
'%20fill='%232c3e50'%20fill-rule='evenodd'/%3e%3c/svg%3e)
'%20d='M14,8a6,6,0,1,0,6,6A6,6,0,0,0,14,8Zm0,10.839A4.839,4.839,0,1,1,18.839,14,4.837,4.837,0,0,1,14,18.839Zm1.5-2.526L13.441,14.82a.292.292,0,0,1-.119-.235V10.613a.291.291,0,0,1,.29-.29h.774a.291.291,0,0,1,.29.29v3.428l1.616,1.176a.29.29,0,0,1,.063.406l-.455.627A.292.292,0,0,1,15.5,16.313Z'%20transform='translate(-8%20-8)'%20fill='%232c3e50'/%3e%3c/svg%3e)
'%20d='M10.155,1.625H8.936V.3a.306.306,0,0,0-.3-.3H7.616a.306.306,0,0,0-.3.3v1.32H4.062V.3a.306.306,0,0,0-.3-.3H2.742a.306.306,0,0,0-.3.3v1.32H1.219A1.219,1.219,0,0,0,0,2.843V11.78A1.219,1.219,0,0,0,1.219,13h8.936a1.219,1.219,0,0,0,1.219-1.219V2.843A1.219,1.219,0,0,0,10.155,1.625ZM10,11.78H1.371a.153.153,0,0,1-.152-.152V4.062h8.936v7.565A.153.153,0,0,1,10,11.78Z'%20fill='%232c3e50'/%3e%3c/svg%3e)
'%20d='M4.1,11.944C.642,6.929,0,6.414,0,4.571a4.571,4.571,0,0,1,9.142,0c0,1.843-.642,2.358-4.1,7.373a.572.572,0,0,1-.94,0Zm.47-5.468a1.9,1.9,0,1,0-1.9-1.9A1.9,1.9,0,0,0,4.571,6.476Z'%20transform='translate(0)'%20fill='%232c3e50'/%3e%3c/svg%3e)
'%3e%3cline%20id='Line_151'%20data-name='Line%20151'%20x2='29.522'%20transform='translate(22.5%2022.368)'%20fill='none'%20stroke='%23fff'%20stroke-linecap='round'%20stroke-width='4'/%3e%3cline%20id='Line_152'%20data-name='Line%20152'%20x2='29.522'%20transform='translate(22.5%2032.443)'%20fill='none'%20stroke='%23fff'%20stroke-linecap='round'%20stroke-width='4'/%3e%3cline%20id='Line_153'%20data-name='Line%20153'%20x2='29.522'%20transform='translate(22.5%2042.519)'%20fill='none'%20stroke='%23fff'%20stroke-linecap='round'%20stroke-width='4'/%3e%3c/g%3e%3c/svg%3e)